Search bioRxiv⌕ Search

Biology subjects

Schwartz, R.

Publications and source records attributed to Schwartz, R..

At least 19 recordsLinked to original sources

Scaling and Generalization of Discrete Diffusion Models for Tumor Phylogenies

Tumor phylogenies -- rooted trees encoding clonal ancestry and mutation acquisition -- are central to understanding cancer evolution, yet generating realistic phylogenies remains challenging. We investigate whether discrete graph diffusion can learn the structural constraints of tumor phylogenies directly from data. Working with approximately 12,500 synthetic phylogenies across twelve evolutionary regimes, we train graph transformer models that denoise typed graphs through a learned reverse diffusion process. Scaling experiments reveal a non-monotonic capacity-performance relationship: a mid-scale model achieves high structural validity and close distributional match to held-out data, while a deeper model fails under fixed optimization hyperparameters. Low-data cross-regime experiments show that diverse training produces more transferable representations than single-regime specialization. These results establish that phylogenetic structural constraints can be learned implicitly through unconditional discrete diffusion, suggesting a viable path toward generative models of tumor evolution.

bioinformatics↗

Saturating hepatic clearance drives elevated cfDNA and fragment shortening in cancer

Liquid biopsy studies consistently report both elevated circulating cell-free DNA (cfDNA) concentrations and shortened fragment lengths in cancer. These features are often attributed to tumor-specific processes, despite tumor-derived cfDNA frequently constituting less than 1% of the total. Here, we consider an alternative explanation: Saturation of cfDNA clearance, which prolongs cfDNA circulation time, increases exposure to plasma nucleases and is expected to produce similar fragmentomic signatures independent of tumor burden. By combining a mechanistic model of cfDNA fragmentation with analyses of two independent cancer patient cohorts, and publicly available clearance-perturbation experiments, we demonstrate that elevated cfDNA levels are accompanied by a characteristic leftward shift in fragment length distributions consistent with impaired hepatic clearance. This fragmentation signature becomes more pronounced at higher cfDNA concentrations, is independent of circulating tumor DNA (ctDNA) fraction, is reproducible under experimentally reduced clearance, and is independently prognostic of patient survival. Together, these results identify saturating clearance as a central determinant of cfDNA abundance and fragment length, re-framing cancer-associated fragmentomic patterns as systemic consequences of clearance dynamics rather than tumor burden alone. More broadly, they highlight the value of mechanistic modeling of clearance processes in extracting clinically meaningful signals from cfDNA fragmentation data.

cancer biology↗

Theoretical estimates on the expected number of mutations for reconstructing clonal lineage trees

Phylogenetics, like many subdisciplines of computational biology, faces a growing challenge of dealing with increasingly large and complicated data sets that have been enabled by ever-improving technologies for sequencing. The issue is particularly acute for studies of somatic evolution, such as of single-cell populations in cancers, where vast single-cell data sets may now identify hundreds of thousands of genetically distinct cells with similar scales of mutations distinguishing them. At the same time, the complexity of the biology of somatic evolution has led to complex phylogeny methods that struggle to scale to even modest data sizes. In this paper, we explore the theoretical and empirical basis for one strategy for managing these large data sets: subsampling mutations to solve the computationally challenging phylogeny problem followed by faster solutions for placement of mutations on a putatively known guide tree. We specifically focus on the fundamental question of determining the number of mutations sufficient to recover the true phylogenetic tree at some level of resolution with high probability. We theoretically analyze variants of several common models that underlie popular tools for building clonal lineage trees. We further evaluate the robustness of these theoretical bounds through simulations of these models, extensions of them, and real biological datasets. The results suggest that modest numbers of mutations suffice to reconstruct clonal trees for typical numbers of clones, supporting the sub-sampling approach as a general strategy for managing the challenges of ever-growing data sets.

cancer biology↗

Persistent hindrances to data re-use in single-cell genomics

We report on our experience attempting to re-use published and publicly available single-cell (or single-nucleus) RNA-sequencing studies (scRNA-seq) from the Gene Expression Omnibus (GEO). We screened GEO for human, mouse and rat scRNA-seq studies as potential candidates for inclusion in the Gemma database of re-annotated and re-analyzed transcriptome studies. Using semi-automated and manual curation, we assessed whether GEO datasets included cell-level expression count matrices and cell-type annotations. We found that there are steep challenges to data reuse. Only [~]40% of studies provided readily usable processed count data that could be reliably mapped to GEO metadata, and fewer than 10% included author-provided cell-type annotations. While raw sequencing data were available for the majority of studies, only a small proportion could be re-analyzed automatically without reliance on heuristics. Our findings show that existing practices for single-cell RNA-sequencing data distribution and sharing are insufficient for effective reuse, and highlight the urgent need for repositories to strengthen and enforce submission requirements, particularly for processed data and cell-type annotations.

genomics↗

CITEgeist: Cellular Indexing of Transcriptomes and Epitopes for Guided Exploration of Intrinsic Spatial Trends

BackgroundDysplastic tissue architecture in estrogen receptor-positive (ER+) breast cancer across therapy-naive and therapy-exposed cancer tissues presents unique challenges in the analysis of spatial transcriptomics. Many tools for deconvolution are developed on well-structured tissue architectures such as the 10x Genomics mouse hippocampus dataset. Spatial transcriptomics analysis could offer valuable insights into treatment response, but faces limitations in cellular resolution. MethodsTo address this problem, we developed CITEgeist, a computational tool for spatial transcriptomic deconvolution using integrated proteomics data from the same slide. Visium Antibody Capture technology was applied alongside our novel algorithm to analyze the tumor microenvironment. We demonstrate the reliability of our method using pre- and post-treatment samples from six breast cancer cases. ResultsOur approach revealed previously undetectable cellular interactions within the tumor microenvironment. By taking an interoperable approach to software development and grounding our algorithm in interpretable variables, we demonstrate how CITEgeist deconvolution is not only accurate but robust enough to be directly used as input in external analytical tools developed by other research teams. We then applied this approach to a set of specimens from a prospective trial our group ran and further validated the findings in a series of in vitro experiments as a demonstrated use case of the utility, necessity, and flexibility of CITEgeist; and the potential of our method to rapidly translate novel clinical samples to new biological insights. ConclusionsCITEgeist addresses a critical technical gap in spatial multi-omics analysis through an integrated, multi-disciplinary approach. This work demonstrates the value of combining clinical, translational, and computational expertise to identify novel mechanisms of treatment resistance, potentially transforming therapeutic strategies for resistant disease.

cancer biology↗

Deconvolution and Phylogeny Inference of Diverse Variant Types Integrating Bulk DNA-seq with Single-cell RNA-seq

MotivationReconstructing clonal lineage trees ("tumor phylogenetics") has become a core tool of cancer genomics. Earlier approaches based on bulk DNA sequencing (DNA-seq) have largely given way to single-cell DNA-seq (scDNA-seq), which offers far greater resolution for clonal substructure. Available data has lagged behind computational theory, though. While single-cell RNA-seq (scRNA-seq) has become widely available, scDNA-seq is still sufficiently costly and technically challenging to preclude routine use on large cohorts. This forces difficult tradeoffs between the limited genome coverage of scRNA-seq, limited availability of scDNA-seq, and limited clonal resolution of bulk DNA-seq. These limitations are especially problematic for studying structural variations and focal copy number variations that are crucial to cancer progression but difficult to observe in RNA-seq. ResultsWe develop a method, TUSV-int, combining advantages of these various genomic technologies by integrating bulk DNA-seq and scRNA-seq data into a single deconvolution and phylogenetic inference computation while allowing for single nucleotide variant (SNV), copy number alteration (CNA) and structural variant (SV) data. We accomplish this by using integer linear programming (ILP) to deconvolve heterogeneous variant types and resolve them into a clonal lineage tree. We demonstrate improved deconvolution performance over comparative methods lacking scRNA-seq data or using more limited variant types. We further demonstrate the power of the method to better resolve clonal structure and mutational histories through application to a previously published DNA-seq/scRNA-seq breast cancer data set. AvailabilityThe source code for TUSV-int is available at https://github.com/CMUSchwartzLab/TUSV-INT.git

cancer biology↗

Computationally reconstructing the evolution of cancer progression risk

Understanding the evolution of cancer in its early stages is critical to identifying key drivers of cancer progression and developing better early diagnostics or prophylactic treatments. Early cancer is difficult to observe, though, since it is generally asymptomatic until extensive genetic damage has accumulated. In this study, we develop a computational approach to infer how once-healthy cells enter into and become committed to a pathway of aggressive cancer. We accomplish this through a strategy of using tumor phylogenetics to look backwards in time to earlier stages of tumor development combined with machine learning to infer how progression risk changes over those stages. We apply this paradigm to point mutation data from a set of cohorts from the Cancer Genome Atlas (TCGA) to formulate models of how progression risk evolves from the earliest stages of tumor growth, as well as how this evolution varies within and between cohorts. The results suggest general mechanisms by which risk develops as a cell population commits to aggressive cancer, but with significant variability between cohorts and individuals. These results imply limits to the potential for earlier diagnosis and intervention while also providing grounds for hope in extending these beyond current practice. AvailabilityThe code used to conduct the analysis is available at: https://github.com/kefanc2/CancerRisk

bioinformatics↗

Predicting locus phylogenetic utility using machine learning

Disentangling evolutionary signal from noise in genomic datasets is essential to building phylogenies. The efficiency of current sequencing platforms and workflows has resulted in a plethora of large-scale phylogenomic datasets where, if signal is weak, it can be easily overwhelmed with non-phylogenetic signal and noise. However, the nature of the latter is not well understood. Although certain factors have been investigated and verified as impacting the accuracy of phylogenetic reconstructions, many others (as well as interactions among different factors) remain understudied. Here we use a large simulation-based dataset and machine learning to better understand the factors, and their interactions, that contribute to species tree error. We trained Random Forest regression models on the features extracted from simulated alignments under known phylogenies to predict the phylogenetic utility of the loci. Loci with the worst utility were then filtered out, resulting in an improved signal-to-noise ratio across the dataset. We investigated the relative importance of different features used by the model, as well as how they correspond to the originally simulated properties. We further used the model on several diverse empirical datasets to predict and subset the least reliable loci and re-infer the phylogenies. We measure the impacts of the subsetting on the overall topologies, difficult nodes identified in the original studies, as well as branch length distribution. Our results suggest that subsetting based on the utility predicted by the model can improve the topological accuracy of the trees and their average statistical support, and limits paralogy and its effects. Although the topology generated from the filtered datasets may not always be dramatically different from that generated from unfiltered data, the worst loci consistently yielded different topologies and worst statistical support, indicating that our protocol identified phylogenetic noise in the empirical data.

evolutionary biology↗

Marker selection strategies for circulating tumor DNA guided by phylogenetic inference

MotivationBlood-based profiling of tumor DNA ("liquid biopsy") has offered great prospects for non-invasive early cancer diagnosis, treatment monitoring, and clinical guidance, but require further advances in computational methods to become a robust quantitative assay of tumor clonal evolution. We propose new methods to better characterize tumor clonal dynamics from circulating tumor DNA (ctDNA), through application to two specific questions: 1) How to apply longitudinal ctDNA data to refine phylogeny models of clonal evolution, and 2) how to quantify changes in clonal frequencies that may be indicative of treatment response or tumor progression. We pose these questions through a probabilistic framework for optimally identifying maximum likelihood markers and applying them to characterizing clonal evolution. ResultsWe first estimate a distribution over plausible clonal lineage models, using bootstrap samples over pre-treatment tissue-based sequence data. We then refine these lineage models and the clonal frequencies they imply over successive longitudinal samples. We use the resulting framework for modeling and refining tree distributions to pose a set of optimization problems to select ctDNA markers to maximize measures of utility capturing ability to solve the two questions of reducing uncertain in phylogeny models or quantifying clonal frequencies given the models. We tested our methods on synthetic data and showed them to be effective at refining distributions of tree models and clonal frequencies so as to minimize measures of tree distance relative to the ground truth. Application of the tree refinement methods to real tumor data further demonstrated their effectiveness in refining a clonal lineage model and assessing its clonal frequencies. The work shows the power of computational methods to improve marker selection, clonal lineage reconstruction, and clonal dynamics profiling for more precise and quantitative assays of tumor progression. Availabilityhttps://github.com/CMUSchwartzLab/Mase-phi.git. Contactrussells@andrew.cmu.edu

bioinformatics↗

Optimizing Design of Genomics Studies for Clonal Evolution Analysis

Genomic biotechnologies have seen rapid development over the past two decades, allowing for both the inference and modification of genetic and epigenetic information at the single cell level. While these tools present enormous potential for basic research, diagnostics, and treatment, they also raise difficult issues of how to design research studies to deploy these tools most effectively. In designing a study at the population or individual level, a researcher might combine several different sequencing modalities and sampling protocols, each with different utility, costs, and other tradeoffs. The central problem this paper attempts to address is then how one might create an optimal study design for a genomic analysis, with particular focus on studies involving somatic variation, typically for applications in cancer genomics. We pose the study design problem as a stochastic constrained nonlinear optimization problem and introduce a simulation-centered optimization procedure that iteratively optimizes the objective function using surrogate modeling combined with pattern and gradient search. Finally, we demonstrate the use of our procedure on diverse test cases to derive resource and study design allocations optimized for various objectives for the study of somatic cell populations.

bioinformatics↗

Determining Optimal Placement of Copy Number Aberration Impacted Single Nucleotide Variants in a Tumor Progression History

Intratumoral heterogeneity arises as a result of genetically distinct subclones emerging during tumor progression. These subclones are characterized by various types of somatic genomic aberrations, with single nucleotide variants (SNVs) and copy number aberrations (CNAs) being the most prominent. While single-cell sequencing provides powerful data for studying tumor progression, most existing and newly generated sequencing datasets are obtained through conventional bulk sequencing. Most of the available methods for studying tumor progression from multi-sample bulk sequencing data are either based on the use of SNVs from genomic loci not impacted by CNAs or designed to handle a small number of SNVs via enumerating their possible copy number trees. In this paper, we introduce DETOPT, a combinatorial optimization method for accurate tumor progression tree inference that places SNVs impacted by CNAs on trees of tumor progression with minimal distortion on their variant allele frequencies observed across available samples of a tumor. We show that on simulated data DETOPT provides more accurate tree placement of SNVs impacted by CNAs than the available alternatives. When applied to a set of multi-sample bulk exome-sequenced tumor metastases from a treatment-refractory, triple-positive metastatic breast cancer, DETOPT reports biologically plausible trees of tumor progression, identifying the tree placement of copy number state gains and losses impacting SNVs, including those in clinically significant genes.

cancer biology↗

Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)

Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed in somatic evolution and of the processes by which they develop. The present work seeks to enhance the power and versatility of tools for single-cell lineage reconstruction by making more comprehensive use of the range of molecular variant types by which tumors evolve. We introduce Sc-TUSV-ext, an integer linear programming (ILP) based tumor phylogeny reconstruction method that, for the first time, integrates single nucleotide variants (SNV), copy number alterations (CNA) and structural variations (SV) into clonal lineage reconstruction from single-cell DNA sequencing data. We show on synthetic data that accounting for these variant types collectively leads to improved accuracy in clonal lineage reconstruction relative to prior methods that consider only subsets of the variant types. We further demonstrate the effectiveness on real data in resolving clonal evolution in the presence of multiple variant types, providing a path towards more comprehensive insight into how various forms of somatic mutability collectively shape tissue development.

cancer biology↗

Modeling the effect of spatial structure on solid tumor evolution and ctDNA composition

Circulating tumor DNA (ctDNA) monitoring, while sufficiently advanced to reflect tumor evolution in real time and inform on cancer diagnosis, treatment, and prognosis, mainly relies on DNA that originates from cell death via apoptosis or necrosis. In solid tumors, chemotherapy and immune infiltration can induce spatially variable rates of cell death, with the potential to bias and distort the clonal composition of ctDNA. Using a stochastic evolutionary model of boundary-driven growth, we study how elevated cell death on the edge of a tumor can simultaneously impact driver mutation accumulation and the representation of tumor clones and mutation detectability in ctDNA. We describe conditions in which invasive clones end up over-represented in ctDNA, clonal diversity can appear elevated in the blood, and spatial bias in shedding can inflate subclonal variant allele frequencies (VAFs). Additionally, we find that tumors that are mostly quiescent can display similar biases, but are far less detectable, and the extent of perceptible spatial bias strongly depends on sequence detection limits. Overall, we show that spatially structured shedding might cause liquid biopsies to provide highly biased profiles of tumor state. While this may enable more sensitive detection of expanding clones, it could also increase the risk of targeting a subclonal variant for treatment. Our results indicate that the effects and clinical consequences of spatially variable cell death on ctDNA composition present an important area for future work.

cancer biology↗

A Simulator for Somatic Evolution Study Design

MotivationSomatic evolution plays a key role in development, cell differentiation, and normal aging, but also diseases such as cancer, which is now mainly thought of as a disease of genetic and epigenetic modification. Understanding mechanisms of somatic mutability -- variant types and frequencies, phylogenetic structure, mutational signatures, and clonal heterogeneity -- and how they can vary between cell lineages will likely play a crucial role in biological discovery and medical applications. This need has led to a proliferation of new technologies for profiling single-cell variation, each with distinctive capabilities and limitations that can be leveraged alone or in combination with other technologies. The enormous space of options for assaying somatic variation, however, presents unsolved informatics problems with regards to selecting optimal combinations of technologies for designing appropriate studies for any particular scientific questions. Versatile simulation tools are needed to make it possible to explore and optimize potential study designs if researchers are to deploy multiomic technologies effectively. ResultsIn this paper, we present a simulator allowing for the generation of synthetic data from a wide range of clonal lineages, variant classes, and sequencing technology choices, intended to provide a platform for effective study design in somatic lineage analysis. Our simulation framework allows for the assessment of study design setups and their statistical validity in determining different ground-truth cancer mechanisms. The user is able to input various properties of the somatic evolutionary system, mutation classes (e.g., single nucleotide polymorphisms, copy number changes, and classes of structural variation), and biotechnology options (e.g., coverage, bulk vs single cell, whole genome vs exome, error rate, number of samples) and can then generate samples of synthetic sequence reads and their corresponding ground-truth parameters for a given study design. We demonstrate the utility of the simulator for testing and optimizing study designs for various experimental queries. Contactrussells@andrew.cmu.edu Availabilityhttps://github.com/CMUSchwartzLab/MosaicSim

bioinformatics↗

SARS-CoV-2 infection results in lasting and systemic perturbations post recovery

SARS-CoV-2 has been found capable of inducing prolonged pathologies collectively referred to as Long-COVID. To better understand this biology, we compared the short- and long-term systemic responses in the golden hamster following either SARS-CoV-2 or influenza A virus (IAV) infection. While SARS-CoV-2 exceeded IAV in its capacity to cause injury to the lung and kidney, the most significant changes were observed in the olfactory bulb (OB) and olfactory epithelium (OE) where inflammation was visible beyond one month post SARS-CoV-2 infection. Despite a lack of detectable virus, OB/OE demonstrated microglial and T cell activation, proinflammatory cytokine production, and interferon responses that correlated with behavioral changes. These findings could be corroborated through sequencing of individuals who recovered from COVID-19, as sustained inflammation in OB/OE tissue remained evident months beyond disease resolution. These data highlight a molecular mechanism for persistent COVID-19 symptomology and characterize a small animal model to develop future therapeutics.

microbiology↗

ConTreeDP: A consensus method of tumor trees based on maximum directed partition support problem

Phylogenetic inference has become a crucial tool for interpreting cancer genomic data, but continuing advances in our understanding of somatic mutability in cancer, genomic technologies for profiling it, and the scale of data available have created a persistent need for new algorithms able to deal with these challenges. One particular need has been for new forms of consensus tree algorithms, which present special challenges in the cancer space for dealing with heterogeneous data, short evolutionary time scales, and rapid mutation by a wide variety of somatic mutability mechanisms. We develop a new consensus tree method for clonal phylogenetics, ConTreeDP, based on a formulation of the Maximum Directed Partition Support Consensus Tree (MDPSCT) problem. We demonstrate theoretically and empirically that our approach can efficiently and accurately compute clonal consensus trees from cancer genomic data. Availability: https://github.com/CMUSchwartzLab/ConTreeDP

bioinformatics↗

De novo Prediction of Cell-Drug Sensitivities Using Deep Learning-based Graph Regularized Matrix Factorization

Application of artificial intelligence (AI) in precision oncology typically involves predicting whether the cancer cells of a patient (previously unseen by AI models) will respond to any of a set of existing anticancer drugs, based on responses of previous training cell samples to those drugs. To expand the repertoire of anticancer drugs, AI has also been used to repurpose drugs that have not been tested in an anticancer setting, i.e., predicting the anticancer effects of a new drug on previously unseen cancer cells de novo. Here, we report a computational model that addresses both of the above tasks in a unified AI framework. Our model, referred to as deep learning-based graph regularized matrix factorization (DeepGRMF), integrates neural networks, graph models, and matrix-factorization techniques to utilize diverse information from drug chemical structures, their impact on cellular signaling systems, and cancer cell cellular states to predict cell response to drugs. DeepGRMF learns embeddings of drugs so that drugs sharing similar structures and mechanisms of action (MOAs) are closely related in the embedding space. Similarly, DeepGRMF also learns representation embeddings of cells such that cells sharing similar cellular states and drug responses are closely related. Evaluation of DeepGRMF and competing models on Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) datasets show its superiority in prediction performance. Finally, we show that the model is capable of predicting effectiveness of a chemotherapy regimen on patient outcomes for the lung cancer patients in The Cancer Genome Atlas (TCGA) dataset.*

bioinformatics↗

Interpretable deep learning for chromatin-informed inference of transcriptional programs driven by somatic alterations across cancers

Cancer is a disease of gene dysregulation, where cells acquire somatic and epigenetic alterations that drive aberrant cellular signaling. These alterations adversely impact transcriptional programs and cause profound changes in gene expression. Interpreting somatic alterations within context-specific transcriptional programs will facilitate personalized therapeutic decisions but is a monumental task. Toward this goal, we develop a partially interpretable neural network model called Chromatin-informed Inference of Transcriptional Regulators Using Self-attention mechanism (CITRUS). CITRUS models the impact of somatic alterations on transcription factors and downstream transcriptional programs. Our approach employs a self-attention mechanism to model the contextual impact of somatic alterations. Furthermore, CITRUS uses a layer of hidden nodes to explicitly represent the state of transcription factors (TFs) to learn the relationships between TFs and their target genes based on TF binding motifs in the open chromatin regions of tumor samples. We apply CITRUS to genomic, transcriptomic, and epigenomic data from 17 cancer types profiled by The Cancer Genome Atlas. CITRUS predicts patient-specific TF activities and reveals transcriptional program variations between and within tumor types. We show that CITRUS yields biological insights into delineating TFs associated with somatic alterations in individual tumors. Thus, CITRUS is a promising tool for precision oncology.

bioinformatics↗